At this Reform meeting, participants debated how to ensure affordability and access in the NHS over the coming years. The roundtable seminar was recorded and transcribed.

“The seminar showed that while many policy experts agree with VBP [Value-Based Pricing] in principle there are a number of concerns in practice. Many welcomed the ambition to expand the assessment of value beyond NICE’s narrow focus on quality-adjusted life years (QALY). Yet with drug companies no longer free to set prices it is still not clear how different “value” will be priced and whether payors will reward the full value of new treatments” p1

See full transcript: Affordability and access:Pharmaceuticals and value for money in the NHS. Roundtable seminar. Reform, Tues 28th Feb 2012.